References
Csurhes PA, Sullivan A-A, Green K, Greer JM, Pender MP, McCombe PA (2005) Increased circulating T cell reactivity to GM1 ganglioside in patients with Guillain–Barré syndrome. J Clin Neurosci 12(4):409–415
Gaudy-Marqueste C, Monestier S, Franques J, Cantais E, Richard M-A, Grob J-J (2013) A severe case of ipilimumab-induced guillain–barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother 36(1):77–78
Naidoo J, Page D, Li B et al (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26(12):2375–2391
Wilgenhof S, Neyns B (2011) Anti-CTLA-4 antibody-induced Guillain–Barré syndrome in a melanoma patient. Ann Oncol 22(4):991–993
Yuki N, Hartung H-P (2012) Guillain–Barré syndrome. N Engl J Med 366(24):2294–2304
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Rights and permissions
About this article
Cite this article
Jacob, A., Unnikrishnan, D.C., Mathew, A. et al. A case of fatal Guillain–Barre syndrome from anti-PD1 monoclonal antibody use. J Cancer Res Clin Oncol 142, 1869–1870 (2016). https://doi.org/10.1007/s00432-016-2191-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-016-2191-7